Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Post by Sonny7on Mar 11, 2014 1:12pm
281 Views
Post# 22308636

This is Normal

This is NormalIn the face of FDA approval, the buzzards were already circling and thinking that they were smelling blood. Considering the November failure from FDA and the subsequent market reaction, there were tens of millions of shares in Canadian markets alone that were picked up between 3 and 5 to 7 cents etc. Any prudent retail trader would capitalize on this news and take profits. Now we are back to square one but it's a new game. With FDA approval there can be non dilutive financing and the company is also ripe to make a deal with a medical tech company and I have an opinion on who may be a likely suitor. The CEO does have his job to do and he will be busy in the next little while but I believe he will come through. It all is what it is, so wasting energy on meowing about the CEO has about as much value as belly aching about the Govt and although it's a popular hobby, it really doesn't serve anyone in a positive way. Personally, I look forward to more days in the sunshine and seeing this play out as a good investment. My Opinion
Bullboard Posts